Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GOOW | 46.96 | 1.06 | +2.30% |
| Roundhill GOOGL WeeklyPay ETF | |||
| LCDS | 73.25 | 0.81 | +1.12% |
| JPMorgan Fundamental Data Science Large Core ETF (LCDS) | |||
| VXUS | 83.44 | 0.78 | +0.94% |
| Vanguard Total International Stock ETF (VXUS) | |||
| XHS | 147.85 | 0.26 | +0.18% |
| State Street SPDR S&P Health Care Services ETF (XHS) | |||
| SH | 32.66 | -0.42 | -1.27% |
| ProShares Short S&P500 (SH) | |||
A.I.dvisor indicates that over the last year, SRZN has been loosely correlated with DRUG. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SRZN jumps, then DRUG could also see price increases.
| Ticker / NAME | Correlation To SRZN | 1D Price Change % | ||
|---|---|---|---|---|
| SRZN | 100% | +2.00% | ||
| DRUG - SRZN | 34% Loosely correlated | -6.22% | ||
| LITS - SRZN | 33% Loosely correlated | +0.86% | ||
| RCUS - SRZN | 32% Poorly correlated | -1.48% | ||
| DMAC - SRZN | 32% Poorly correlated | +0.21% | ||
| BCYC - SRZN | 32% Poorly correlated | -2.12% | ||
More | ||||
Industry Biotechnology
SRZN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend. In 48 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SRZN as a result. In 73 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for SRZN just turned positive on October 27, 2026. Looking at past instances where SRZN's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +5.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRZN advanced for three days, in 247 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 156 of 180 cases where SRZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.666) is normal, around the industry mean (3.498). P/E Ratio (-0.774) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.837) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SRZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.